BT-001 Market Summary

Key Factors Driving BT-001 Growth

1. Novel dual-payload oncolytic virus platform

BT-001 is an oncolytic vaccinia virus engineered to express both a human anti-CTLA-4 antibody and GM-CSF directly within the tumor microenvironment. This localized delivery is designed to maximize antitumor immunity while minimizing the systemic immune-related toxicities typically associated with CTLA-4 blockade, providing a strong differentiating factor versus conventional checkpoint inhibitors.

2. Encouraging early clinical efficacy supports further development

Updated Phase I/IIa data presented at ESMO 2024 demonstrated tumor regression in heavily pretreated patients who had previously failed anti-PD-(L)1 therapy. BT-001, particularly in combination with pembrolizumab, showed early clinical responses, including responses in 2 of 6 evaluable patients receiving combination therapy, while maintaining a favorable safety profile. Translational analyses also showed conversion of immunologically "cold" tumors into "hot" tumors with increased T-cell infiltration.

3. Combination strategy expands commercial opportunity

BT-001 is being evaluated together with KEYTRUDA® (pembrolizumab), potentially broadening its use across multiple advanced solid tumors. Since PD-1 inhibitors are standard treatment across melanoma, head and neck cancer, renal cell carcinoma, NSCLC, and other malignancies, demonstrating synergy with pembrolizumab could substantially increase the addressable patient population.

4. Regulatory progress supports global development

The U.S. FDA cleared the IND application in 2021, enabling enrollment of U.S. patients into the multinational Phase I/IIa study. Expansion into U.S. clinical sites strengthens the regulatory pathway and increases the attractiveness of BT-001 for future licensing or commercialization partnerships.

5. Potential best-in-class tumor-selective immunotherapy

Unlike systemic CTLA-4 antibodies, BT-001 produces its therapeutic payload primarily within tumors, where viral replication occurs. Early translational studies reported undetectable systemic exposure to the expressed anti-CTLA-4 antibody while maintaining immune activation within tumors, potentially offering an improved therapeutic index that could differentiate BT-001 in the competitive immuno-oncology landscape.

BT-001 Recent Developments

In June 2022, BioInvent and Transgene announced a clinical trial collaboration and supply agreement with MSD to evaluate BT‑001 in combination with KEYTRUDA (pembrolizumab) in the Phase I/IIa solid‑tumor trial.

Under this agreement, MSD supplies pembrolizumab for use in the trial; BioInvent and Transgene retain responsibility for BT‑001 development, with the combination intended to broaden efficacy in PD‑1‑refractory solid tumors.

“BT-001 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of BT-001 for potential indication like Autoimmune disorders in the 7MM. A detailed picture of BT-001’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the BT-001 for potential indications. The BT-001 market report provides insights about BT-001’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current BT-001 performance, future market assessments inclusive of the BT-001 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of BT-001 sales forecasts, along with factors driving its market.

BT-001 Drug Summary

BT-001 is an investigational intratumorally administered oncolytic vaccinia virus–based immunotherapy developed by Transgene in collaboration with BioInvent International for the treatment of advanced solid tumors. Developed using Transgene's Invir.IO® platform, BT-001 is engineered to selectively replicate within tumor cells while expressing a human anti-CTLA-4 antibody and granulocyte-macrophage colony-stimulating factor (GM-CSF) directly in the tumor microenvironment. This dual mechanism is designed to induce direct tumor cell lysis, enhance local immune activation, and promote systemic antitumor immune responses while minimizing the systemic toxicity commonly associated with checkpoint inhibitors. BT-001 is currently being evaluated in Phase I/II clinical trials as both a monotherapy and in combination with anti-PD-1 therapy in patients with advanced or metastatic solid tumors, where early clinical data have demonstrated a manageable safety profile, evidence of viral replication within tumors, local expression of the therapeutic transgenes, and encouraging preliminary signs of antitumor activity. The report provides BT-001’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the BT-001 Market Report

The report provides insights into:

• A comprehensive product overview including the BT-001 MoA, description, dosage and administration, research and development activities in potential indication like Autoimmune disorders.
• Elaborated details on BT-001 regulatory milestones and other development activities have been provided in BT-001 market report.
• The report also highlights BT-001‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The BT-001 market report also covers the patents information, generic entry and impact on cost cut.
• The BT-001 market report contains current and forecasted BT-001 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The BT-001 market report also features the SWOT analysis with analyst views for BT-001 in potential indications.

Methodology

The BT-001 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BT-001 Analytical Perspective by DelveInsight

• In-depth BT-001 Market Assessment

This BT-001 sales market forecast report provides a detailed market assessment of BT-001 for potential indication like Autoimmune disorders in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted BT-001 sales data uptil 2034.

• BT-001 Clinical Assessment

The BT-001 market report provides the clinical trials information of BT-001 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

BT-001 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

BT-001 Market Potential & Revenue Forecast

• Projected market size for the BT-001 and its key indications
• Estimated BT-001 sales potential (BT-001 peak sales forecasts)
• BT-001 Pricing strategies and reimbursement landscape

BT-001 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• BT-001 Market positioning compared to existing treatments
• BT-001 Strengths & weaknesses relative to competitors

BT-001 Regulatory & Commercial Milestones

• BT-001 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

BT-001 Clinical Differentiation

• BT-001 Efficacy & safety advantages over existing drugs
• BT-001 Unique selling points

BT-001 Market Report Highlights

• In the coming years, the BT-001 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The BT-001 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BT-001’s dominance.
• Other emerging products for Autoimmune disorders are expected to give tough market competition to BT-001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of BT-001 in potential indications.
• Analyse BT-001 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted BT-001 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of BT-001 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of BT-001? How strong is BT-001’s clinical and commercial performance?
• What is BT-001’s clinical trial status in each individual indications such as Autoimmune disorders and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BT-001 Manufacturers?
• What are the key designations that have been granted to BT-001 for potential indications? How are they going to impact BT-001’s penetration in various geographies?
• What is the current and forecasted BT-001 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of BT-001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to BT-001 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is BT-001? What is the duration of therapy and what are the geographical variations in cost per patient?